Effect of Low-dose Intravitreal Bevacizumab and Ranibizumab on Regression and Late Reactivation in Retinopathy of Prematurity in the Treatment-Naïve Eyes
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 6 (4) , 328-330
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trialThe Lancet, 2019
- A Dosing Study of Bevacizumab for Retinopathy of PrematurityOphthalmology, 2018
- Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of PrematurityJAMA Ophthalmology, 2017
- Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab MonotherapyOphthalmology, 2016
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- The International Classification of Retinopathy of Prematurity RevisitedArchives of Ophthalmology (1950), 2005
- Revised Indications for the Treatment of Retinopathy of PrematurityArchives of Ophthalmology (1950), 2003